Visit the ACCC COVID-19 Resource Center & Discussion Group for Insights on Providing Optimal Patient Care During the Pandemic.
Home / BiomarkerLive / Overview



The importance of biomarkers and molecular profiling for cancer diagnosis and treatment continues to grow. As the science and knowledge around biomarkers expands, it is challenging for cancer care providers to adequately keep up with this rapidly evolving area; for practices, hospitals, and health systems to develop processes for integration of appropriate testing; and to efficiently implement molecular testing to improve patient care as information and innovation continue to accelerate.

Operational issues including insurance coverage, reimbursement, and insufficient protocols were among the common barriers to biomarker testing cited by respondents to ACCC's 2018 Trending Now in Cancer Care survey.

Through BiomarkerLIVE, ACCC seeks to raise awareness about biomarker testing and integration into the oncology care continuum, increase access to patient and provider education materials, educate the multidisciplinary care team, curate vetted and designated resources, and establish a strong network of advocacy and professional partners to help facilitate the integration of precision medicine into everyday practice.

Through this project ACCC intends to:

  • Investigate the existing resources available to providers and patients relevant to biomarker testing.
  • Better understand the current terminology used by members of the multidisciplinary cancer care team, external pathology or laboratory groups, and disease-specific advocacy organizations.
  • Develop new tools and platforms to disseminate relevant educational resources and tools to the multidisciplinary cancer care team.
For more information about this project, please contact Janelle Schrag, MPH, Senior Program Manager, ACCC Provider Education.

Presentations & Abstracts

News & Press

Our Partners



Our Supporters

logo-abbvie-200x80 This project is supported by AbbVie, Lilly Oncology, and Merck & Co., Inc. BMS-330x80 Phase one of this project was supported by Bristol Myers Squibb.